Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 May 21;15:79. doi: 10.1186/s12933-016-0395-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2016

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — Three-dimensional assessment of the neointimal distribution. a The lumen and stent areas were manually traced every 1 mm. b The neointimal area was divided into 360 circumferential sectors (each section is 1°, which is referenced from the lumen’s center). The mean neointimal thickness (NIT) was calculated for each sector in each 1-mm section, and the same sector’s thicknesses were compared throughout the entire stented segment. c To visualize the two-dimensional layout, the stent surface was cut along the longitudinal direction and flattened into a rectangular shape. The roughness of the neointima (variability in NIT) within the whole stent was evaluated based on the standard deviation (SD) of the NITs from the same 1°-sector along the entire stented segment. Representative cases are shown for a patient with high mean amplitude of glycemic excursion (MAGE) (d) and a patient with low MAGE (e)